REG - Tissue Regenix Group - Financial update and funding plans

Tissue RegenixAnnouncement

07/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251107:nRSG5855Ga&default-theme=true

RNS Number : 5855G  Tissue Regenix Group PLC  07 November 2025

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

Financial update and funding plans

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides
an update to its financial position.

 

Further to the announcement of 22 October 2025 and the temporary suspension of
trading on AIM of the Company's ordinary shares, the new Senior Leadership
Team has been reviewing the previously announced restatement of revenue
numbers for the financial year ended 31 December 2024 ("FY24"), the impact
this has on H125 adjusted EBITDA, and the cash-position and ongoing expected
performance of the business.

 

It is now clear to the Senior Leadership Team that the Company has a
substantial backlog of creditors, and very limited cash balances. Accordingly,
the Company has an urgent need to raise capital by the end of November.
Without additional funding the Company will not be able to continue to trade.

 

The Company is in discussion with its major shareholders and has clear
indications of support to raise approximately £5m by way of a convertible
loan note. Any fundraise will be subject to shareholder approval.

 

Further updates will be made in due course.

 

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Jay LeCoque, Executive Chairman                            via Walbrook PR

 Cavendish Capital Markets (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                     Tel: +44 (0) 20 7466 5000

 Nigel Birks - Life Science Specialist Sales

 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                          Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth                         Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

 

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under
the UK Market Abuse Regulation. With the publication of this announcement,
this information is now considered to be in the public domain.

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFFFVFLRLRIIE



            Copyright 2019 Regulatory News Service, all rights reserved